EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)

Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis

Fariba M Donovan iD, Royce H Johnson, Thomas F Patterson iD, Martin Hoenigl, Andrej Spec, Monica K Sikka, Steven M Holland, Shmuel Shoham, Joanna M Schaenman iD, Sanjay R Mehta, Rasha A Kuran iD, John N Galgiani iD und 3 weitere

Annals of Internal Medicine · 2026-09 · 179 (9) · 1254-1261

DOI: 10.7326/annals-26-00103 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Internal Medicine, 2026-09. Verfasst von Fariba M Donovan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Valley Fever Center for Excellence, University of Arizona College of Medicine - Tucson; Division of Infectious Diseases, Department of Medicine, Univ…. Hauptthemen laut MEDLINE: Coccidioidomycosis, Antifungal Agents, Pyrimidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Olorofim, a novel dihydroorotate dehydrogenase inhibitor, may be efficacious in patients with disseminated coccidioidomycosis (DCM) who lack alternative treatment options. OBJECTIVE: To evaluate olorofim effectiveness and adverse events in patients with DCM. DESIGN: Single-group, open-label, phase 2b study. (ClinicalTrials.gov: NCT03583164). SETTING: Ten U.S. sites. PARTICIPANTS: Forty-one patients with DCM and limited or no treatment options. Patients received olorofim alone or in combination with ongoing standard of care during an 84-day main treatment phase. Extended treatment was offered to patients. MEASUREMENTS: Mycoses Study Group-European Organization for Research and Treatment of Cancer (MSG-EORTC) criteria for global response based on subcategories of clinical, radiologic, and mycologic response were adjudicated by an independent data review committee (DRC) at days 42 and 84 (main treatment phase). Because the slow pace of serologic improvement in DCM limits global response to stable at best, this article focuses on patient clinical responses. Treatment-emergent adverse events (TEAEs) were compiled for both treatment phases. RESULTS: Forty-one patients with DCM were enrolled from May 2019 to August 2022. Thirty-nine (95.1%) did not have immunosuppression. Central nervous system disease was present in 30 (73.2%) patients, and 13 (43.3%) had a ventriculoperitoneal shunt with or without an Ommaya reservoir. Clinical success as adjudicated by the DRC occurred in 31 of 41 patients (75.6% [95% CI, 59.7% to 87.6%]) at day 42 and 30 of 41 patients (73.2% [CI, 57.1% to 85.8%]) at day 84. The main TEAE was hepatic biochemistry elevation in 9 of 41 patients (21.9%), which was managed by liver enzyme monitoring and dose reduction or pause in 8 patients (19.5%) and drug discontinuation in 1 patient (2.4%). LIMITATION: This was a single-group, open-label trial, but a randomized controlled trial would be preferable. CONCLUSION: Olorofim showed effectiveness in patients with DCM with limited or no therapeutic options. PRIMARY FUNDING SOURCE: F2G, Ltd.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CoccidioidomycosisAntifungal AgentsPyrimidinesHumansFemaleMiddle AgedMaleAgedAdultDihydroorotate DehydrogenaseAcetamidesPiperazinesPyrroles

Substanzen

Antifungal AgentsolorofimPyrimidinesDihydroorotate DehydrogenaseAcetamidesPiperazinesPyrroles

Autor:innen und Institutionen

  • Valley Fever Center for Excellence, University of Arizona College of Medicine - Tucson; Division of Infectious Diseases, Department of Medicine, University of Arizona College of Medicine - Tucson; and BIO5 Institute, Un…
  • Division of Infectious Diseases, Department of Medicine, Kern Medical, Bakersfield, California, and Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California…
  • University of Texas Health Science Center at San Antonio, San Antonio, Texas (T.F.P.).
  • Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Graz, Austria (M.H.).
  • Division of Infectious Disease, Washington University in St. Louis School of Medicine, St. Louis, Missouri (A.S.).
  • Division of Infectious Diseases, Department of Medicine, Oregon Health & Science University, Portland, Oregon (M.K.S.).

ORCID-Profile: Fariba M Donovan, Thomas F Patterson, Joanna M Schaenman, Rasha A Kuran, John N Galgiani, John H Rex, George R Thompson

Zitieren

APA

Donovan, F. M., Johnson, R. H., Patterson, T. F., Hoenigl, M., Spec, A., Sikka, M. K., Holland, S. M., Shoham, S., Schaenman, J. M., Mehta, S. R., Kuran, R. A., Galgiani, J. N., Bresnik, M., Rex, J. H., & Thompson, G. R. (2026). Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis. Annals of Internal Medicine, 179(9), 1254-1261. https://doi.org/10.7326/annals-26-00103

Vancouver

Donovan FM, Johnson RH, Patterson TF, Hoenigl M, Spec A, Sikka MK, et al. Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis. Annals of Internal Medicine. 2026;179(9):1254-1261. doi:10.7326/annals-26-00103

BibTeX
@article{Donovan2026,
  author = {Donovan, Fariba M and Johnson, Royce H and Patterson, Thomas F and Hoenigl, Martin and Spec, Andrej and Sikka, Monica K and Holland, Steven M and Shoham, Shmuel and Schaenman, Joanna M and Mehta, Sanjay R and Kuran, Rasha A and Galgiani, John N and Bresnik, Mark and Rex, John H and Thompson, George R},
  title = {Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis},
  journal = {Annals of Internal Medicine},
  year = {2026},
  volume = {179},
  number = {9},
  pages = {1254--1261},
  doi = {10.7326/annals-26-00103}
}
Kostenlos starten →